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Cochrane Collaborative Review Group on Peripheral Vascular Diseases: 
Review Abstracts 
Introduction 
F. G. R. Fowkes 
The following abstracts are part of an ongoing quarterly series of articles produced by the Cochrane Collaborative 
Review Group on Peripheral Vascular Diseases. The reviews are published in full on the Cochrane Library, a 
quarterly electronic journal available on CD ROM. This format allows Cochrane reviews to accommodate n w 
data as it becomes available, making the library a consistently up-to-date source of reformation over time. 
If you are interested in writing a Cochrane review or becoming a member of the Peripheral Vascular Diseases 
Group please contact: 
Professor FGR Fowkes 
Cochrane Collaborative Review Group on Peripheral Vascular Diseases 
Department of Pubhc Health Sciences 
University of Edinburgh 
Teviot Place 
Edinburgh EH8 9AG 
UK 
Tel. +44 (0) 131 650 3220 
Fax. +44 (0) 131 650 6904 
E-mail" gerry.fowkes@ed.ac.uk 
Any comments or criticisms on Cochrane PVD reviews/abstracts should be made through the comments/ 
criticisms facility on the Cochrane Library, or by contacting the group directly at the above address. 
Key areas for review Reviews in vrogress 
Thrombolys~s for cr~tzcal limb ischaemia Optimum conduit for femoro-popliteal bypass grafting 
Laser versus other types of angioplasty Grafts used m abdommaI aortic aneurysm repalr 
Antibwt~cs for bypass urgery IV flulds in abdominal aortic surgery 
Antibiotics for amputations Fibrinolytic agents for thrombolysls of arterial and 
Rutosides for chromc venous insufficiency graft occlusion 
Surgery for PAOD Surgery versus thrombolysis for acute hmb ischaemza 
Vasodilators for peripheral arterial &sease Surgical treatment of deep venous incompetence 
Compresszon stockings for the preventwn of DVT 
Prostanoids for the treatment of arteriaI/mixed ulcers 
Calcmm antagonists for Raynaud's disorder 
Sclerotherapy for vamcose veins 
Sterozds, cyclophosphmmde and plasma exchange for 
Polyarteritis Nodosa 
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Abstracts 
Abstract: Angioplasty (Versus Non-surgical distances did not show a greater improvement m the 
Management) for Intermittent Claudication angioplasty group. At 2 years of follow-up in one trial 
F.G.R. Fowkes and I.N. Gillespie the angioplasty group were more likely to have a 
Date of most recent substantive amendment: patent artery, OR 5.5 (95% CI 1.8, 17.0) but not a 
19 February 1998 significantly better walking distance or quality of life. 
In the other trial, long-term follow-up at 6 years dem- 
onstrated no significant differences in outcome be- 
Objectives tween the angioplasty and control groups. 
To determme if angioplasty of arteries in the leg is 
more effective than non-surgical therapy or no therapy Conclusions 
in patients with mild to moderate intermittent clau- 
dication. These limited results suggest hat angloplasty may 
have had a short-term benefit, but this may not have 
been sustained. Further large scale trials are required. 
Meanwhile, widespread use of angioplasty for mild 
Search Strategy to moderate claudication cannot be recommended. 
Trials were identified using the search strategy of the 
Peripheral Vascular Diseases Review Group, reviewmg 
lists in papers and conference proceedings, and cor- 
responding with selected authors. 
Abstract: Fixed dose subcutanous low molecular 
weight heparins versus adjusted dose unfractionated 
Selection Criteria heparin for venous thromboembolism 
A.G.M. van den Belt, M.H. Prins, A.W.A. Lensing, Trials were selected for inclusion by one reviewer 
and comprised only trials of mild or moderate inter- A.A. Castro, O.A.C. Clark, A.N. Atallah and 
mittent claudication in which patients were randomly E. Burihan 
allocated to angioplasty or conservative treatment. Date of most recent substantive amendment: 
Lesions amenable to angloplasty had to be dem- 14 January 1998 
onstrated on angiography or duplex scanning. 
Objectives 
Data Collection and Analysis To evaluate the efficacy and safety of fixed-dose sub- 
cutaneous low molecular weight heparins compared 
Data from each trial were obtainedby one reviewer and to adjusted dose intravenous or subcutaneous un- 
included the following outcomes: treadmill walking fractionated heparin for the initial treatment of patients 
distances, ankle brachial pressure mdex, duplex scan- with acute deep venous thrombosis or pulmonary 




Computerised searches of MEDLINE, EMBASE and 
Data were obtained from two trials. At 6 months of LILACS, and hand-searching relevant journals for all 
follow-up, mean ankle brachial pressure radices were publications describing randomised clinical trials of 
higher in the angioplasty groups than control groups, low molecular weight heparins in the treatment of 
WMD 0.17 (95% confidence interval (CI) 0.11, 0.24). venous thromboembolism. Additionally, randomised 
In one trial walking distances were greater in the clinical trials were searched through personal com- 
angioplasty group, but in the other trial in which munication with colleagues and representatives of
controls underwent an exercise programme, walkmg pharmaceutical companies. 
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Selection Criteria the 2158 patmnts in the low molecular weight heparin 
group versus 43 (2.0%) of the 2196 patients in the un- 
Only truly randomlsed clinical trials comparing fixed- fractionated heparin group suffered a major haem- 
dose subcutaneous low molecular weight heparin with orrhage. At the end of follow-up in the low molecular 
adjusted dose intravenous or subcutaneous un- weight heparin group, 94 (5.2%) of the 1803 patients 
fractionated heparin in patients with venous throm- had died versus 125 (6.9%) of the 1816 patients m the 
boembolism were included, unfractionated heparin group. This was also a stat- 
istically significant reduction. 
The analysis of stu&es in patients with proximal deep 
venous thrombosis (five studies, 1636 patients) showed Data Collection and Analysis 
a statistically significant reduction in the incidence of 
recurrent venous thromboembolic events at the end of The search strategy, the inclusion of studies, and the 
follow-up in favour of low molecular weight heparin 
evaluation of outcome data on the change in veno- (OR 0.60; 95% CI 0.40-0.89). At the end of follow-up 39 
graphic score comparing pre- and post-treatment veno- 
grams, the incidence of symptomatic recurrent venous (4.8%) of the 814 patients allocated to low molecular 
thromboembolism during initial treatment and during weight heparin versus 64 (7.8%) of the 822 patients in the 
follow-up, the frequency of major haemorrhagic epi- unfractionated heparin group had a recurrent venous 
sodes during the initial treatment period, and the over- thromboembolic event. In this specific group of patients 
all mortality at the end of follow-up were performed by the reduction in the frequency of major haemorrhagic 
two independent reviewers, episodes and in the overall mortality with low mo- 
The main analysis included all trials m patients with lecular weight heparin was also statistically significant. 
In patients with pulmonary embolism, however, the 
venous thromboembohsm. Additional analyses were reduction in recurrent venous thromboembolic events 
done for specific groups of patients including (i) 
was relatively small, with a wide 95% confidence in- patients with proximal deep venous thrombosis; (ii) 
patients with pulmonary embolism; and (iii) patients terval (OR 0.91, 95% CI 0.42-1.97). 
The analysis of studies with reported adequate con- 
with malignant disease, cealment of treatment allocation prior to randomisation 
(six studies, 3218 patients) demonstrated a statistically 
non-significant reduction in recurrent venous throm- 
Main Results boembolism during the initial treatment, and a stat- 
istically non-significant reduction in overall mortality at 
Compared to the current standard therapy with un- the end of follow-up in favour of low molecular weight 
fractionated heparin in patients with venous throm- heparin treatment. 
boembolism, the therapy with low molecular weight 
heparm demonstrated a statistically non-significant re- 
duction in recurrent venous thromboembolism of ap- Conclusion 
proximately 25% during the imtial treatment, at 3 or 6 
months' follow-up, or at the end of follow-up. At the The efficacy and safety of low molecular weight heparin 
end of follow-up 76 (4.2%) of the 1803 patients allocated treatment in patients with deep venous thrombosis 
to low molecular weight heparin had thrombotic om- and/or pulmonary embollsim was shown to be at least 
plications versus 101 (5.6%) of the 1816 patients al- as effective as unfractionated heparin treatment. The 
located to unfractlonated heparin (OR 0 75; 95% outcomes concerning the safety of low molecular 
confidence interval (CI) 0.55-1.01). Of the patients in- weight heparin, the occurrence of major haemorrhage 
cluded in this analysis, approximately 25% had pul- during the initial treatment and overall mortality at the 
monary embolism. A statistically significant difference end of follow-up, demonstrated a statistically slg- 
in venographic outcome was demonstrated m favour nificant reduction in favour of low molecular weight 
of low molecular weight heparin. A reduction of the heparin. We conclude that low molecular weight hep- 
thrombus ize on venogram occurred in 62% of low arin can be safely adopted as the standard therapy in 
molecular weight heparin treated patients and in 53% patmnts with deep venous thrombosis. Therefore, stud- 
of patients treated with unfractionared heparin. The ies comparing the individual low molecular weight 
observed reduction with low molecular weight heparin heparins with each other in these patients will be jus- 
m the frequency of major haemorrhaglc episodes dur- tlfied. Although the results in patients with pulmonary 
ing the initial treatment was also statistically sig- embolism are promising, it would be prudent o await 
nificant. At the end of the mltlal period 23 (1.1%) of further esults of new studies. 
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